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A B S T R A C T
Background
A limited number of studies have assessed the risk of common diseases when combining
information from several predisposing polymorphisms. In most cases, individual polymor-
phisms only moderately increase risk (;20%), and they are thought to be unhelpful in
assessing individuals’ risk clinically. The value of analyzing multiple alleles simultaneously is not
well studied. This is often because, for any given disease, very few common risk alleles have
been confirmed.
Methods and Findings
Three common variants (Lys23 of KCNJ11, Pro12 of PPARG, and the T allele at rs7903146 of
TCF7L2) have been shown to predispose to type 2 diabetes mellitus across many large studies.
Risk allele frequencies ranged from 0.30 to 0.88 in controls. To assess the combined effect of
multiple susceptibility alleles, we genotyped these variants in a large case-control study (3,668
controls versus 2,409 cases). Individual allele odds ratios (ORs) ranged from 1.14 (95%
confidence interval [CI], 1.05 to 1.23) to 1.48 (95% CI, 1.36 to 1.60). We found no evidence of
gene-gene interaction, and the risks of multiple alleles were consistent with a multiplicative
model. Each additional risk allele increased the odds of type 2 diabetes by 1.28 (95% CI, 1.21 to
1.35) times. Participants with all six risk alleles had an OR of 5.71 (95% CI, 1.15 to 28.3)
compared to those with no risk alleles. The 8.1% of participants that were double-homozygous
for the risk alleles at TCF7L2 and Pro12Ala had an OR of 3.16 (95% CI, 2.22 to 4.50), compared to
4.3% with no TCF7L2 risk alleles and either no or one Glu23Lys or Pro12Ala risk alleles.
Conclusions
Combining information from several known common risk polymorphisms allows the
identification of population subgroups with markedly differing risks of developing type 2
diabetes compared to those obtained using single polymorphisms. This approach may have a
role in future preventative measures for common, polygenic diseases.
The Editors’ Summary of this article follows the references.
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Introduction
An increasing number of common gene variants (minor
allele frequency . 5%) reproducibly associate with polygenic
disease. With some exceptions, such as complement factor H
variation and age-related macular degeneration [1–3], these
variants only mildly predispose to disease, with allelic ORs
generally below1.5. These common, low-penetrance risk alleles
may explain much of the genetic component of complex
multifactorial disease [4]. In addition to providing important
etiological insights, identifying risk alleles could help define
groups of people at relatively high or low risk of developing a
disease. Some previous theoretical papers based on simulated
data have demonstrated the potential utility of combining
information from multiple common, low-penetrance variants
for complex disease prediction [5,6]. However, studies using
real data have been limited to either combinations of relatively
rare variants [5], pairs of risk polymorphisms [7,8], variants that
individually have not been established as risk alleles [9], and
prospective cohorts that are disadvantaged by a small number
of cases on follow-up [10].
Type 2 diabetes is a typical complex, polygenic disease for
which several common risk alleles have been identified. In this
studywehave defined a reproducibly associated type 2 diabetes
variant as one in which an association from a meta-analysis of
published studies has reached genome-wide levels of signifi-
cance. Using this definition, alleles of PPARG (Pro12) [11],
KCNJ11 (Lys23) [12–14], and TCF7L2 (T at rs7903146) [15] have
been reproducibly associated with type 2 diabetes. Individu-
ally, each of these polymorphisms onlymoderately predisposes
to type 2 diabetes with odds ratios (ORs) ranging from ;1.15
for the Lys23 variant of the KCNJ11 variant to ;1.50 for the
rs7903146 variant of TCF7L2. Throughout this paper we use
Pro12, Lys23, and ‘‘T at rs7903146’’ to refer to the risk alleles in
the genes PPARG, KCNJ11, and TCF7L2, respectively.
The aim of this study was to examine the joint effects of
replicated type 2 diabetes variants on disease risk in a large
case-control study. To do this we studied 2,409 type 2 diabetes
cases and 3,668 population-based controls, both cases and
controls drawn from a population of white UK residents.
Methods
Participants
The clinical characteristics of the cases and controls are
shown in Table 1. Informed consent was obtained from all
participants. Participants have been described in detail [16].
Briefly, all participants with type 2 diabetes were unrelated
and of white UK origin who had diabetes defined either by
WHO criteria [17] or by being treated with medication for
diabetes, and were recruited from four sources: (i) a
collection of young-onset (defined as  45 years at age of
diagnosis) patients with type 2 diabetes; (ii) probands from
type 2 diabetic sibships from the Warren 2 sibling pairs
described previously [18,19]; (iii) a collection of patients with
type 2 diabetes (Warren 2 cases) diagnosed between ages 35
and 65 y, but not selected on family history; (iv) and probands
from a collection of families that had either both parents
available, or one parent and at least two siblings [20].
Population control participants were all UK whites. These
were recruited from three sources: (i) parents from a
consecutive birth cohort (Exeter Family Study) with normal
(,6.0 mmol/l) fasting glucose and/or normal HbA1c levels
(,6%; Diabetes Control and Complications trial corrected)
[18]; (ii) a nationally recruited population control sample of
UK whites obtained from the European Cell Culture
Collection (ECACC), and (iii) an ongoing follow-up study of
all people born in Great Britain during one week in 1958
(National Child Development Study, http://www.cls.ioe.ac.uk/
Cohort/Ncds/mainncds.htm). Cases and families in which the
proband had high GAD autoantibody levels (.99th percentile
of the normal population) were excluded from the study.
Known subtypes of diabetes (e.g., MODY, maturity onset
Table 1. Clinical Details of Study Participants
Variable Cases Controls
Number 2,409 3,668
Male gender (%) 58 50
Age at diagnosis or testing, years (SD)a 48.7 (9.7) 31.8 (5.7)
Body mass index, kg/m2 (SD) 31.4 (6.4) 27.2 (4.3)
Treatment, D/O/I, % 13/62/25 b
Only successfully genotyped participants are included. No clinical details were available
for the ECACC or 1958 Birth Cohort population control samples, so control characteristics
are for the EFS samples only.
aAge at diagnosis for case subjects, age at study for control subjects.
bControl subjects were not on treatment.
D, dietary hypoglycemic agent; I, insulin; O, oral hypoglycemic agent; SD, standard
deviation
DOI: 10.1371/journal.pmed.0030374.t001
Table 2. Individual SNP and Gene-Gene Interaction ORs
Analysis Polymorphism Cases, n (MAF) Controls, n (MAF) OR (95% CI)a p-Value
Individual polymorphism analysis Glu23Lys 2,332 (0.384) 3,592 (0.354) 1.14 (1.05 to 1.23) 0.001
Pro12Ala 2,347 (0.099) 3,293 (0.123) 1.29 (1.14 to 1.45) 4 3 105
rs7903146 2,229 (0.384) 3,538 (0.300) 1.48 (1.36 to 1.60) 3 3 1021
Pairwise interaction analysis Glu23Lys Pro12Ala 2,306 3,229 0.98 (0.82 to 1.17) 0.561b
Glu23Lys 3 rs7903146 2,162 3,485 0.90 (0.80 to 1.01) 0.178b
Pro12Ala 3 rs7903146 2,180 3,176 0.85 (0.70 to 1.02) 0.062b
Three-way 2,146 3,131 0.95 (0.89 to 1.01) 0.105b
aIndividual SNP ORs and pairwise gene-gene interaction ORs are shown. Interaction ORs are from case-control logistic regression analysis.
bp-Values based on Chi2 association statistic in 33 3 table from case-only analysis.
MAF, minor allele frequency
DOI: 10.1371/journal.pmed.0030374.t002
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diabetes of the young) were excluded by clinical criteria and/
or genetic testing.
There was no evidence of heterogeneity of individual single
nucleotide polymorphism (SNP) allele frequencies between
case groups or control groups (all p . 0.01). We therefore
pooled case groups and control groups in our analysis. The
lactase polymorphism rs4988235, which varies 2-fold in
frequency across the UK [21], is not associated with type 2
diabetes in our population (OR¼0.97 [95% CI, 0.90 to 1.06], p
¼ 0.52), suggesting that population stratification is unlikely in
our study (unpublished data).
Genotyping
Except for the Pro12Ala variant in the 1958 birth cohort,
genotyping was performed by KBioscience (Herts, UK) using
a modified TaqMan-based assay, details of which can be found
at their website (http://www.kbioscience.co.uk). The Pro12Ala
genotypes in the 1958 birth cohort were genotyped using
TaqMan. Genotyping accuracy, as determined from the
genotype concordance between duplicate samples (9.5% of
the overall sample) was 99.6%. The genotyping success rate
was 94.7% for controls and 95.6% for cases. All poly-
morphisms were in Hardy-Weinberg equilibrium in cases
and controls (all p . 0.05).
Statistical Analysis
We used logistic regression for association tests. This
method assumes a multiplicative allelic effect, such that each
allele independently increases odds of disease. We tested for
deviation from the logistic model by testing goodness of fit
for both the individual SNP and the full model. For the
interaction analysis we used case-control and case-only
designs. The case-only analysis tests for independence of
alleles in a case group, and can be more powerful than the
case-control test, assuming that the variants are independent
in the general population [22]. We used Quanto for power
calculations [22]. To determine the positive predictive value
of the type 2 diabetes risk alleles we used the likelihood ratio
method of Yang et al. [5]. The likelihood ratios were
estimated from the logistic regression model parameters.
Using this approach the likelihood ratio is multiplied by the
pretest probability of the disease to estimate the post-test
probability of the disease. We used Stata SE version 9.1 (Stata,
College Station, Texas, United States) to generate the receiver
operating characteristic (ROC) curve and for calculating the
area under the curve.
Results
First we confirmed that the individual polymorphisms were
predisposing to type 2 diabetes in these samples. The ORs for
individual variants are shown in Table 2 and are similar to
those observed in other large studies [11–13,15]. Some of the
individual polymorphism results have been published pre-
viously [12,23], although for this study further case and
control samples were tested to increase statistical power when
looking for interaction between alleles. At each of these
variants, our data (and that from the literature) are consistent
with each risk allele independently increasing the odds of
type 2 diabetes (i.e., individually all variants fit a multi-
plicative inheritance model); goodness of fit p-values are 0.81,
0.92, and 0.99 for Glu23Lys, Pro12Ala, and rs7903146,
respectively.
We next looked for potential gene-gene interaction
between the three variants and type 2 diabetes status (i.e.,
deviation from a multiplicative model) using logistic regres-
sion. We used both case-only and case-control designs [22].
Power to detect interaction ORs for pairs of SNPs are shown
in Figure 1. We had 80% power to detect pairwise interaction
ORs of 1.18 to 1.28 at p  0.05, depending on the
combination of polymorphisms. A pairwise interaction OR
of 1.25 means, in the example of a pair of alleles each with
main effect ORs of 1.2, that the joint OR is increased from
1.44 (no interaction) to 1.8 (i.e., 1.23 1.23 1.25).
Gene-gene interaction results are shown in Table 2. No
pairwise or three-way combinations of genotypes showed
evidence of interaction. While our results suggest that these
variants increase risk in a simple multiplicative manner, it is
important to note that we cannot rule out a range of other
joint effects models. For example, our data are also consistent
with an additive model of gene-gene interaction; however,
because the ORs for the individual polymorphisms are low,
our study is poorly powered to distinguish between an
additive and multiplicative model.
The proportion of participants with increasing numbers of
risk alleles in cases and in controls are shown in Figure 2. The
ORs for type 2 diabetes for individuals carrying increasing
Figure 1. Power to Detect Interaction ORs for Combinations of SNPs
The power calculations assume a multiplicative mode of inheritance.
Estimates of allele frequencies and expected effect size were determined
from the literature; our study frequencies and effects sizes are consistent
with these. a was set at 0.05. The power calculations were performed
using Quanto [22].
DOI: 10.1371/journal.pmed.0030374.g001
Figure 2. The Distribution of Risk Alleles in the Controls and Cases
Controls are indicated by black bars, cases by white bars.
DOI: 10.1371/journal.pmed.0030374.g002
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numbers of risk alleles are shown in Figure 3, in comparison
to the 4.5% of those that have no or only one risk allele. This
reference group was chosen because only 0.25% of individ-
uals carry zero risk alleles. The progressive increase in ORs is
consistent with an independent effects multiplicative model
(goodness of fit test p ¼ 0.49). Each additional risk allele
increased odds of disease by 1.28 (95% CI, 1.21 to 1.35) times.
Participants with six risk alleles had an OR of 2.84 (95% CI,
2.08 to 3.87) compared to the reference group. Because of the
relatively large influence of the rs7903146 on type 2 diabetes
risk, Table S1 provides ORs for all different combinations of
risk alleles. The 8.1% of participants who are double-
homozygous for risk alleles at Pro12Ala and rs7903146 have
an OR of 3.16 (95% CI, 2.22 to 4.50), p¼1.531010, compared
to the 4.3% in the reference group. If the 1% of persons with
all six risk alleles are compared to the 0.25% of those with
zero risk alleles, the OR is 5.71 (95% CI, 1.15 to 28.3), p¼ 0.03.
An alternative way to assess the impact of susceptibility
alleles on disease risk is to use positive predictive values.
Assuming a background risk of 5% in the general population,
the probability of people with zero risk alleles developing
type 2 diabetes is 2% compared to 10% for people with all six
risk alleles.
Discussion
This study examined how combining information from
three highly replicated SNPs alters the relative risk of type 2
diabetes in case-control studies. It is the first study, to our
knowledge, to look at the impact of the combined predictive
value of three common (allele frequencies 0.3–0.88) genetic
variants that have individually reached genomewide signifi-
cance in meta-analysis. We showed that there is no evidence
for interaction (within the limits of this study’s power), and
that the prediction of relative risk is greater when the three
alleles are combined in a manner that is consistent with a
multiplicative model.
Because there are only three confirmed common type 2
diabetes risk variants, the predictive power of this genetic
information is still small compared to environmental and
lifestyle influences such as body mass index and physical
activity [24]. Considerable cause for optimism remains,
however, that common type 2 diabetes risk polymorphisms
will provide meaningful predictive information. Janssens et
al. have suggested that the predictive power of genetic tests
should be evaluated by the area under the ROC curve (AUC)
[25]. The AUC is a measure of the discriminatory power of the
test. A perfect test would have an AUC of 1; a test with no
discriminatory power would have an AUC of 0.5. The ROC
curve for the three polymorphisms described here is plotted
in Figure 4; the area under the ROC curve is 0.58. There are
two reasons to think that this figure will improve with time
and that genetic screening in type 2 diabetes will eventually
prove useful. First, the number of reproducibly associated
variants is likely to increase rapidly with large clinical
resources and the technology to perform whole-genome
association studies in place. Yang et al. estimated that 20–25
risk variants with allele frequencies greater than 0.1 and ORs
of 1.5 are required for an AUC of about 0.8 [5,26]. Second, the
low cost of genotyping may mean identifying a small
proportion of individuals at high risk would still be justifiable
if preventative measures can be found.
One minor limitation of our study is that our cases are
enriched for patients with a family history of type 2 diabetes
and a young age of diagnosis. This may mean that, compared
to the general type 2 diabetes population, we have over-
estimated the risk due to these variants. This should be offset,
to some extent, by our use of a relatively young population-
based cohort as our control group, approximately 5% of
whom will develop diabetes later in life. We also note that the
ORs we observed are consistent with those from other large
studies in the literature. However, to assess the applicability
of our findings to the general population, further studies will
be needed—ideally large, prospective cohort studies. This will
require use of future resources such as the UK Biobank,
which is currently in the early stages of recruiting 500,000
individuals from the general UK population [27]. These very
large-scale studies will also be needed to give us the adequate
power to compare risk of disease in patients with the high
numbers of risk alleles, and to identify subtle interaction
effects.
It has been suggested that gene-gene and gene-environ-
ment interactions play a major role in complex disease
Figure 3. ORs and 95% CIs for Participants Carrying Increasing Numbers
of Risk Alleles
The reference group is individuals with zero or one risk allele.
DOI: 10.1371/journal.pmed.0030374.g003
Figure 4. ROC for the Information Provided by the Glu23Lys, Pro12Ala,
and rs7903146 Variants after Fitting a Logistic Regression Model
AUC¼ 0.58.
DOI: 10.1371/journal.pmed.0030374.g004
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predisposition. We found no evidence of gene-gene inter-
action between the variants we studied and type 2 diabetes
risk. If some of the yet-unidentified variants interact with
each other and/or with environmental factors, we will be able
to further (and perhaps dramatically) increase the predictive
power of polygenic variant information. However, based on
our results, even in the absence of interaction the combina-
tion of information from several common, low-penetrance
alleles may provide a good level of predictive power in
persons with high numbers of risk alleles.
Despite limitations to this study, we feel that important
conclusions can be drawn from our results. Our data support
the idea that, while individual polygenic susceptibility
variants may be of limited use in disease prediction, the
combined information from a number of these variants
allows the identification of groups of people at high and low
risk of developing a complex disease [5,6]. This approach may
allow the targeting of preventative measures to individuals at
high risk of disease, although many further studies will be
required to examine the efficacy of preventative measures in
groups with high-risk genotypes.
In conclusion, although individual susceptibility alleles
only moderately increase the risk of type 2 diabetes, the risk is
multiplicatively increased when risk alleles are combined.
The combined information from risk alleles allows the
identification of subgroups of the population with odds for
disease significantly greater than when using a single poly-
morphism.
Supporting Information
Table S1. ORs and 95% CIs for Different Combinations of Risk
Alleles
Data are given for participants carrying differing combinations of
risk alleles compared with those with zero TCF7L2 risk alleles and
zero or one Glu23Lys/Pro12Ala risk allele for type 2 diabetes status
(Ref). NS, no participants
Found at DOI: 10.1371/journal.pmed.0030374.st001 (41 KB DOC).
Accession Numbers
The RefSeq (http://www.ncbi.nlm.nih.gov/RefSeq) accession numbers
for TCF7L2 is NM_030756; for PPARG is NM_005037; for KCNJ11 is
NM_000525 and for Lactase is NM_002299.
Acknowledgments
We thank John Todd, Neil Walker, and David Strachan for providing
the data for the Pro12Ala variant in the 1958 birth cohort. Michael
Weedon is a Vandervell Foundation research fellow. Andrew
Hattersley is a Wellcome Trust Research Leave Fellow. We acknowl-
edge use of DNA from the British 1958 Birth Cohort collection (http://
www.cls.ioe.ac.uk/Cohort/Ncds/mainncds.htm), funded by the Medical
Research Council grant G0000934 and the Wellcome Trust grant
068545/Z/02.
Author contributions. MNW, MIM, CJG, EZ, NWR, ATH, and TMF
were involved in the design and implementation of the study. MNW,
MIM, CJG, EZ, NWR, ATH, and TMF were involved in the writing up
of the study. MIM, GH, MW, BS, KRO, and ATH were involved in the
design and execution of studies to collect DNA samples. All authors
contributed to and read the final manuscript.
References
1. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, et al. (2005)
Complement factor H polymorphism and age-related macular degener-
ation. Science 308: 421–424.
2. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. (2005)
Complement factor H variant increases the risk of age-related macular
degeneration. Science 308: 419–421.
3. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. (2005) Complement
factor H polymorphism in age-related macular degeneration. Science 308:
385–389.
4. Reich DE, Lander ES (2001) On the allelic spectrum of human disease.
Trends Genet 17: 502–510.
5. Yang Q, Khoury MJ, Botto L, Friedman JM, Flanders WD (2003) Improving
the prediction of complex diseases by testing for multiple disease-
susceptibility genes. Am J Hum Genet 72: 636–649.
6. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, et al. (2002)
Polygenic susceptibility to breast cancer and implications for prevention.
Nat Genet 31: 33–36.
7. Hansen SK, Nielsen EM, Ek J, Andersen G, Glumer C, et al. (2005) Analysis
of separate and combined effects of common variation in KCNJ11 and
PPARG on risk of type 2 diabetes. J Clin Endocrinol Metab 90: 3629–3637.
8. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, et al. (2005)
Hypothetical LOC387715 is a second major susceptibility gene for age-
related macular degeneration, contributing independently of complement
factor H to disease risk. Hum Mol Genet 14: 3227–3236.
9. Jackson AE, Cassell PG, North BV, Vijayaraghavan S, Gelding SV, et al.
(2004) Polymorphic variations in the neurogenic differentiation-1, neuro-
genin-3, and hepatocyte nuclear factor-1alpha genes contribute to glucose
intolerance in a South Indian population. Diabetes 53: 2122–2125.
10. Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjogren M, et al.
(2005) Genetic prediction of future type 2 diabetes. PLoS Med 2: 1299–
1308.
11. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl M-C, et al.
(2000) The common PPARg Pro12Ala polymorphism is associated with
decreased risk of type 2 diabetes. Nat Genet 26: 76–80.
12. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, et al. (2003)
Large-scale association studies of variants in genes encoding the pancreatic
beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8)
confirm that the KCNJ11 E23K variant is associated with type 2 diabetes.
Diabetes 52: 568–572.
13. Florez JC, Burtt N, de Bakker PI, Almgren P, Tuomi T, et al. (2004)
Haplotype structure and genotype-phenotype correlations of the sulfony-
lurea receptor and the islet ATP-sensitive potassium channel gene region.
Diabetes 53: 1360–1368.
14. Nielsen EM, Hansen L, Carstensen B, Echwald SM, Drivsholm T, et al. (2003)
The E23K variant of Kir6.2 associates with impaired post-OGTT serum
insulin response and increased risk of type 2 diabetes. Diabetes 52: 573–
577.
15. Grant SFA, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, et
al. (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers
risk of type 2 diabetes. Nat Genet 38: 320–323.
16. Weedon M, Owen K, Shields B, Hitman G, Walker M, et al. (2004) Common
variants of the HNF4alpha P2 promoter are associated with type 2 diabetes
in the UK population. Diabetes 53: 3002–3006.
17. WHO Study Group (1999) Report of a WHO Consultation: Part 1:
Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health
Organisation: Geneva.
18. Minton JA, Hattersley AT, Owen K, McCarthy MI, Walker M, et al. (2002)
Association studies of genetic variation in the WFS1 gene and type 2
diabetes in U.K. populations. Diabetes 51: 1287–1290.
19. Wiltshire S, Hattersley AT, Hitman GA, Walker M, Levy JC, et al. (2001) A
genomewide scan for loci predisposing to type 2 diabetes in a U.K.
population (the Diabetes UK Warren 2 Repository): Analysis of 573
pedigrees provides independent replication of a susceptibility locus on
chromosome 1q. Am J Hum Genet 69: 553–569.
20. Frayling T, Walker M, McCarthy M, Evans J, Allen L, et al. (1999) Parent-
offspring Trios: A resource to facilitate the identification of type 2 diabetes
genes. Diabetes 48: 2475–2479.
21. Campbell CD, Ogburn EL, Lunetta KL, Lyon HN, Freedman ML, et al.
(2005) Demonstrating stratification in a European American population.
Nat Genet 37: 868–872.
22. Gauderman WJ (2002) Sample size requirements for association studies of
gene-gene interaction. Am J Epidemiol 155: 478–484.
23. Zeggini E, Parkinson JRC, Halford S, Owen KR, Walker M, et al. (2005)
Examining the relationships between the Pro12Ala variant in PPARG and
Type 2 diabetes-related traits in UK samples. Diabet Med 22: 1696–1700.
24. Sargeant LA, Wareham NJ, Khaw KT (2000) Family history of diabetes
identifies a group at increased risk for the metabolic consequences of
obesity and physical inactivity in EPIC-Norfolk: A population-based study.
The European Prospective Investigation into Cancer. Int J Obes Relat Metab
Disord 24: 1333–1339.
25. Janssens A, Pardo MC, Steyerberg EW, van Duijn CM (2004) Revisiting the
clinical validity of multiplex genetic testing in complex diseases. Am J Hum
Genet 74: 585–588.
26. Yang QH, Khoury MJ, Friedman JM, Little J, Flanders WD (2005) How many
genes underlie the occurrence of common complex diseases in the
population? Int J Epidemiol 34: 1129–1137.
27. Ollier W, Sprosen T, Peakman T (2005) UK Biobank: From concept to
reality. Pharmacogenomics 6: 639–646.
PLoS Medicine | www.plosmedicine.org October 2006 | Volume 3 | Issue 10 | e3741881
Predicting Type 2 Diabetes
Editors’ Summary
Background. Diabetes is an important and increasingly common global
health problem; the World Health Organization has estimated that about
170 million people currently have diabetes worldwide. One particular
form, type 2 diabetes, develops when cells in the body become unable
to respond to a hormone called insulin. Insulin is normally released by
the pancreas and controls the ability of body cells to take in glucose
(sugar). Therefore, when cells become insensitive to insulin as in people
with type 2 diabetes, glucose levels in the body are not well controlled
and may become dangerously high in the blood. These high levels can
have long-term damaging effects on various organs in the body,
particularly the eyes, nerves, heart, and kidneys. There are many different
factors that affect whether someone is likely to develop type 2 diabetes.
These factors can be broadly grouped into two categories: environ-
mental and genetic. Environmental factors such as obesity, a diet high in
sugar, and a sedentary lifestyle are all risk factors for developing type 2
diabetes in later life. Genetically, a number of variants in many different
genes may affect the risk of developing the disease. Generally, these
gene variants are common in human populations but each gene variant
only mildly increases the risk that a person possessing it will get type 2
diabetes.
Why Was This Study Done? The investigators performing this study
wanted to understand how different gene variants combine to affect an
individual’s risk of getting type 2 diabetes. That is, if a person carries
many different variants, does their overall risk increase a lot or only a
little?
What Did the Researchers Do and Find? First, the researchers surveyed
the published reports to identify those gene variants for which there was
strong evidence of an association with type 2 diabetes. They found
mutations in three genes that had been shown reproducibly to be
associated with type 2 diabetes in different studies: PPARG (whose
product is involved in regulation of fat tissue), KCNJ11 (whose product is
involved in insulin production), and TCF7L2 (whose product is thought to
be involved in controlling sugar levels). Then, they compared two groups
of white people in the UK: 2,409 people with type 2 diabetes (‘‘cases’’),
and 3,668 people from the general population (‘‘controls’’). The
researchers compared the two groups to see which individuals
possessed which gene variants, and did statistical testing to work out
to what extent having particular combinations of the gene variants
affected an individual’s chance of being a ‘‘case’’ versus a ‘‘control.’’
Their results showed that in the groups studied, having an ever-
increasing number of gene variants increased the risk of developing
diabetes. The risk that someone with none of the gene variants would
develop type 2 diabetes was about 2%, while the chance for someone
with all gene variants was about10%.
What Do These Findings Mean? These results show that the risk of
developing type 2 diabetes is greater if an individual possesses all of the
gene variants that were examined in this study. The analysis also
suggests that using information on all three variants, rather than just
one, is likely to be more accurate in predicting future risk. How this
genetic information should be used alongside other well-known
preventative measures such as altered lifestyle requires further study.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030374.
 NHS Direct patient information on diabetes
 National Diabetes Information Clearinghouse information on type 2
diabetes
 World Health Organization Diabetes Programme
 Centers for Disease ControlDiabetes Public Health Resource
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